Recent News

StiRx Co-Authors Strategic Analysis on the Evolving Strategy for Drug-Resistant Gonorrhea

Boston, MA — January 2026 — StiRx announced the publication of a peer-reviewed review article in Current Opinion in Infectious Diseases analyzing the shifting treatment paradigm for drug-resistant Neisseria gonorrhoeae . By contrasting the near-term antibiotic pipeline with longer-horizon biologic and immune-based solutions, the analysis frames a category poised for innovation as resistance undermines legacy therapies. The review highlights that while new oral antibiotics ma

StiRx Showcases Advances in Next-Generation Immunotherapeutics at ISV Congress 2025

Boston, MA – October 2025 — StiRx, a biotechnology company pioneering next-generation biologics for sexually transmitted infections...

StiRx and International Vaccine Institute (IVI) Sign Memorandum of Understanding to Advance Monoclonal Antibody Technologies Against Drug-Resistant Gonorrhea

Boston, MA, August 2025 - StiRx Inc., a biotechnology company pioneering best-in-class vaccines and biologics against sexually...

StiRx Co-Founders Author Critical Review on Biologic Therapies for Sexually Transmitted Infections

Boston, MA, May 2025 — Clinical Microbiology Reviews has published a critical review article authored by StiRx Co-Founders Davinder...